sinovac biotech ltd. is a china-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis a and b, seasonal influenza, h5n1 pandemic influenza (avian flu), h1n1 influenza (swine flu), and mumps, as well as animal rabies vaccine for canines. in 2009, sinovac was the first company worldwide to receive approval for its h1n1 influenza vaccine, panflu.1, and has manufactured it for the chinese central government, pursuant to the government-stockpiling program. the company is also the only supplier of the h5n1 pandemic influenza vaccine to the government-stockpiling program. sinovac is developing a number of new pipeline vaccines including vaccines for enterovirus 71 (against hand, foot, and mouth disease), of which the ev71 vaccine is currently in phase iii clinical trials, pneumococcal conjugate, pneumococcal polysaccharides, and rubella. sinovac sells its vaccine
Company profile
Ticker
SVA
Exchange
Website
CEO
Weidong Yin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NET FORCE SYSTEMS INC
SEC CIK
SVA stock data
Latest filings (excl ownership)
SC TO-T/A
Third party tender offer statement (amended)
15 Mar 24
8-A12B/A
Registration of securities on exchange (amended)
21 Feb 24
6-K
Current report (foreign)
21 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
2 Feb 24
SC 14D9
Tender offer solicitation
18 Jan 24
SC TO-T
Third party tender offer statement
8 Jan 24
UPLOAD
Letter from SEC
10 Oct 23
CORRESP
Correspondence with SEC
5 Oct 23
SC TO-T/A
Third party tender offer statement (amended)
3 Oct 23
6-K
SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection
11 Sep 23
Latest ownership filings
SC 13G/A
Advantech Capital L.P.
20 Mar 24
SC 13D/A
SAIF Partners IV L.P.
4 Dec 23
SC 13D/A
SAIF Partners IV L.P.
15 Sep 23
SC 13D/A
SAIF Partners IV L.P.
25 May 23
SC 13D/A
SAIF Partners IV L.P.
15 Mar 23
SC 13D/A
SAIF Partners IV L.P.
12 Dec 22
SC 13D
CDH Fund VI, L.P.
22 Dec 20
SC 13D/A
1Globe Capital LLC
21 Dec 20
SC 13D/A
Sinovac Biotech LTD
19 Mar 19
SC 13D/A
Sinovac Biotech LTD
27 Aug 18
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
53.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 34 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 2 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 382.89 bn |
Total shares | 53.05 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
1Globe Capital | 18.52 mm | $0.00 |
SAIF Partners IV | 10.78 mm | $0.00 |
CDH Fund VI | 6.00 mm | $0.00 |
Advantech Capital | 5.90 mm | $43.84 mm |
Vivo Capital | 5.90 mm | $38.17 bn |
Orbimed Advisors | 2.72 mm | $340.00 bn |
Renaissance Technologies | 2.38 mm | $1.54 mm |
Neumann Advisory Hong Kong | 315.59 k | $2.04 mm |
STT State Street | 160.88 k | $1.04 bn |
Yorktown Management & Research | 149.79 k | $4.49 mm |